Abstract
Proteomic technologies are being used in an effort to correct some of the deficiencies in traditional drug discovery. Proteins are important targets for drug discovery, particularly for cancer as well because there is a defect in the protein machinery of the cell in malignancy. Because proteome analysis can produce comprehensive molecular description of the differences between normal and diseased states, it can be used to compare the effect of candidate drugs on the disease process. The trend now is to integrate oncoproteomics with oncogenomics for drug discovery and target validation in oncology. Among the large number of proteomic technologies available for this purpose, the most important ones are three-dimensional protein structure determination, protein biochips, laser capture microdissection, and study of protein-protein and protein-drug interactions. Cancer biomarkers and signaling pathways involved in malignancy are important drug targets. The wealth of new information in proteomics databases, along with microarrays and bioinformatics, provides unlimited possibilities for designing new therapeutic agents for cancer. Proteomic approaches will also play an important role in the discovery and development of personalized medicines.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Jain KK. Recent advances in oncoproteomics. Curr Opin Mol Ther 2002; 4:203–209.
Chen G, Gharib TG, Huang CC, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002; 8:2298–2305.
Hanash SM, Madoz-Gurpide J, Misek DE. Identification of novel targets for cancer therapy using expression proteomics. Leukemia 2002; 16:478–485.
Emmert-Buck MR, Gillespie JW, Paweletz CP, et al. An approach to proteomic analysis of human tumors. Mol Carcinog 2000; 27:158–165.
Jain KK. Proteomics: technologies, markets and companies. Basel: Jain PharmaBiotech, 2004.
Jain KK. Application of laser capture microdissection to proteomics. Methods Enzymol 2002; 356:157–167.
Bichsel VE, Liotta LA, Petricoin EF 3rd. Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J 2001; 7:69–78.
Fend F, Raffeld M. Laser capture microdissection in pathology. J Clin Pathol 2000; 53:666–672.
Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003; 3:267–275.
Grubb RL, Calvert VS, Wulkuhle JD, et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 2003; 3:2142–2146.
Li JJ, Fang X, Tan W. Molecular aptamer beacons for real-time protein recognition. Biochem Biophys Res Commun 2002; 292:31–40.
Verma M, Kagan J, Sidransky D, Srivastava S. Proteomic analysis of cancer-cell mitochondria. Nat Rev Cancer 2003; 3:789–795.
Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. PNAS 2003; 100:3410–3415.
Nicosia SV, Bai W, Cheng JQ, et al. Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am 2003; 17:927–943.
McKerrow JH, Bhargava V, Hansell E, et al. A functional proteomics screen of proteases in colorectal carcinoma. Mol Med 2000; 6:450–460.
Ficarro SB, McCleland ML, Stukenberg PT, et al. Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae. Nat Biotechnol 2002; 20: 301–305.
Hao D, Rowinsky EK. Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors. Cancer Invest 2002; 20:387–404.
Glen RC, Allen SC. Ligand-protein docking: cancer research at the interface between biology and chemistry. Curr Med Chem 2003; 10:763–767.
Borbat PP, Costa-Filho AJ, Earle KA, et al. Electron spin resonance in studies of membranes and proteins. Science 2001; 291:266–269.
Enyedy IJ, Ling Y, Nacro K, et al. Discovery of small-molecule inhibitors of Bcl-2 through structurebased computer screening. J Med Chem 2001; 44:4313–4324.
Lindsay MA. Target discovery. Nat Rev Drug Discov 2003; 2:831–838.
Jain KK. Role of oncoproteomics in the personalized management of cancer. Expert Rev Proteomics 2004; 1:49–55.
Fang Y, Frutos AG, Lahiri J. Membrane protein microarrays. J Am Chem Soc 2002; 124:2394–2395.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Jain, K.K. (2005). Proteomics-Based Anticancer Drug Discovery. In: LaRochelle, W.J., Shimkets, R.A. (eds) The Oncogenomics Handbook. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1385/1-59259-893-5:123
Download citation
DOI: https://doi.org/10.1385/1-59259-893-5:123
Publisher Name: Humana Press
Print ISBN: 978-1-58829-425-8
Online ISBN: 978-1-59259-893-9
eBook Packages: MedicineMedicine (R0)